These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 18060072)

  • 21. IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.
    Schwenk R; DeBot M; Porter M; Nikki J; Rein L; Spaccapelo R; Crisanti A; Wightman PD; Ockenhouse CF; Dutta S
    PLoS One; 2014; 9(10):e111020. PubMed ID: 25343487
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.
    Polhemus ME; Magill AJ; Cummings JF; Kester KE; Ockenhouse CF; Lanar DE; Dutta S; Barbosa A; Soisson L; Diggs CL; Robinson SA; Haynes JD; Stewart VA; Ware LA; Brando C; Krzych U; Bowden RA; Cohen JD; Dubois MC; Ofori-Anyinam O; De-Kock E; Ballou WR; Heppner DG
    Vaccine; 2007 May; 25(21):4203-12. PubMed ID: 17442466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A monoclonal antibody-based immunoassay to measure the antibody response against the repeat region of the circumsporozoite protein of Plasmodium falciparum.
    Radin K; Clement F; Jongert E; Sterckx YG; Ockenhouse C; Regules J; Lemiale F; Leroux-Roels G
    Malar J; 2016 Nov; 15(1):543. PubMed ID: 27825382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Re-investigation of the circumsporozoite protein-based induction of sterile immunity against Plasmodium berghei infection.
    Reed RC; Louis-Wileman V; Wells RL; Verheul AF; Hunter RL; Lal AA
    Vaccine; 1996 Jun; 14(8):828-36. PubMed ID: 8817831
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of reconstituted influenza virus virosomes as an immunopotentiating delivery system for a peptide-based vaccine.
    Pöltl-Frank F; Zurbriggen R; Helg A; Stuart F; Robinson J; Glück R; Pluschke G
    Clin Exp Immunol; 1999 Sep; 117(3):496-503. PubMed ID: 10469053
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys.
    Jones TR; Obaldia N; Gramzinski RA; Charoenvit Y; Kolodny N; Kitov S; Davis HL; Krieg AM; Hoffman SL
    Vaccine; 1999 Aug; 17(23-24):3065-71. PubMed ID: 10462241
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunoglobulin G subclass and antibody avidity responses in Malian children immunized with Plasmodium falciparum apical membrane antigen 1 vaccine candidate FMP2.1/AS02
    Berry AA; Gottlieb ER; Kouriba B; Diarra I; Thera MA; Dutta S; Coulibaly D; Ouattara A; Niangaly A; Kone AK; Traore K; Tolo Y; Mishcherkin V; Soisson L; Diggs CL; Blackwelder WC; Laurens MB; Sztein MB; Doumbo OK; Plowe CV; Lyke KE
    Malar J; 2019 Jan; 18(1):13. PubMed ID: 30658710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
    Lalitha PV; Biswas S; Pillai CR; Saxena RK
    Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity of well-characterized synthetic Plasmodium falciparum multiple antigen peptide conjugates.
    Joshi MB; Gam AA; Boykins RA; Kumar S; Sacci J; Hoffman SL; Nakhasi HL; Kenney RT
    Infect Immun; 2001 Aug; 69(8):4884-90. PubMed ID: 11447164
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of protective polyclonal antibodies by immunization with a Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine.
    Wang R; Charoenvit Y; Corradin G; Porrozzi R; Hunter RL; Glenn G; Alving CR; Church P; Hoffman SL
    J Immunol; 1995 Mar; 154(6):2784-93. PubMed ID: 7876549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine.
    Gordon DM; McGovern TW; Krzych U; Cohen JC; Schneider I; LaChance R; Heppner DG; Yuan G; Hollingdale M; Slaoui M
    J Infect Dis; 1995 Jun; 171(6):1576-85. PubMed ID: 7769295
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety, immunogenicity, and pilot efficacy of Plasmodium falciparum sporozoite and asexual blood-stage combination vaccine in Swiss adults.
    Sturchler D; Berger R; Rudin C; Just M; Saul A; Rzepczyk C; Brown G; Anders R; Coppel R; Woodrow G
    Am J Trop Med Hyg; 1995 Oct; 53(4):423-31. PubMed ID: 7485698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment in humans of a synthetic peptide-based vaccine against the sporozoite stage of the human malaria parasite, Plasmodium falciparum.
    Etlinger HM; Felix AM; Gillessen D; Heimer EP; Just M; Pink JR; Sinigaglia F; Stürchler D; Takacs B; Trzeciak A
    J Immunol; 1988 Jan; 140(2):626-33. PubMed ID: 3275719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Head-to-Head Comparison of Soluble vs. Qβ VLP Circumsporozoite Protein Vaccines Reveals Selective Enhancement of NANP Repeat Responses.
    Khan F; Porter M; Schwenk R; DeBot M; Saudan P; Dutta S
    PLoS One; 2015; 10(11):e0142035. PubMed ID: 26571021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A totally synthetic polyoxime malaria vaccine containing Plasmodium falciparum B cell and universal T cell epitopes elicits immune responses in volunteers of diverse HLA types.
    Nardin EH; Calvo-Calle JM; Oliveira GA; Nussenzweig RS; Schneider M; Tiercy JM; Loutan L; Hochstrasser D; Rose K
    J Immunol; 2001 Jan; 166(1):481-9. PubMed ID: 11123327
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody responses to Plasmodium falciparum sporozoite-, liver- and blood-stage synthetic peptides in migrant and autochthonous populations in malaria endemic areas.
    Ferreira-da-Cruz MF; Deslandes DC; Oliveira-Ferreira J; Montenegro-James S; Tartar A; Druilhe P; Daniel-Ribeiro CT
    Parasite; 1995 Mar; 2(1):23-9. PubMed ID: 9137641
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural and immunological analysis of circumsporozoite protein peptides: a further step in the identification of potential components of a minimal subunit-based, chemically synthesised antimalarial vaccine.
    Bermúdez A; Vanegas M; Patarroyo ME
    Vaccine; 2008 Dec; 26(52):6908-18. PubMed ID: 18930095
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasmodium falciparum circumsporozoite vaccine immunogenicity and efficacy trial with natural challenge quantitation in an area of endemic human malaria of Kenya.
    Sherwood JA; Copeland RS; Taylor KA; Abok K; Oloo AJ; Were JB; Strickland GT; Gordon DM; Ballou WR; Bales JD; Wirtz RA; Wittes J; Gross M; Que JU; Cryz SJ; Oster CN; Roberts CR; Sadoff JC
    Vaccine; 1996 Jun; 14(8):817-27. PubMed ID: 8817830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria.
    Malkin EM; Diemert DJ; McArthur JH; Perreault JR; Miles AP; Giersing BK; Mullen GE; Orcutt A; Muratova O; Awkal M; Zhou H; Wang J; Stowers A; Long CA; Mahanty S; Miller LH; Saul A; Durbin AP
    Infect Immun; 2005 Jun; 73(6):3677-85. PubMed ID: 15908397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites.
    Egan JE; Hoffman SL; Haynes JD; Sadoff JC; Schneider I; Grau GE; Hollingdale MR; Ballou WR; Gordon DM
    Am J Trop Med Hyg; 1993 Aug; 49(2):166-73. PubMed ID: 8357078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.